Healthcare Sector Analytics

Market size, company revenue, drug approvals, clinical trials, regulation, hospitals, doctors, drug spending, labs and devices

Brand drug

Humira Pen Crohn's-Uc-Hs(Adalimumab)

Medicare prescription drug cost, prescriptions and prescribers, 2024

$2.7M

Medicare cost, 2023

Medicare drug plans spent on Humira Pen Crohn's-Uc-Hs (adalimumab) in 2024, for prescriptions and refills. Spending fell 42% from 2022 to 2023.

Medicare cost, 2023

$2.7M

-41.6% from 2022

Prescriptions

137

$19,714.04 per claim

Patients

117

113 prescribers

Total spending

-

All plans

Questions and answers

How much does Medicare spend on Humira Pen Crohn's-Uc-Hs?

Medicare prescription drug plans paid $2.7M for Humira Pen Crohn's-Uc-Hs in 2023, for 137 prescriptions and refills to 117 patients (down 41.6% from 2022). The average cost per claim was $19,714.04.

Spending over the years

Medicare spending by year

All plans and makers

Prescriber data: cost by year

By state

Where the prescribers practice, 2024

Medicare cost by state

States with the highest cost

Prescriber data by year

YearPrescribersClaimsPatientsCost
2022202255209$4.6M
2023113137117$2.7M

More drugs: Medicare drug spending and the Prescriptions view.

Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.

LinkedInLinkedInXXYouTubeYouTube